Skip to Content

Humana Inc HUM

Morningstar Rating
$309.01 −7.05 (2.23%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Humana Earnings: Strong Start to 2024, but Management Pulls 2025 Guidance

We are keeping our $473 fair value estimate intact after narrow-moat Humana reported a strong start to 2024, as timing in administrative expenses helped the firm outperform expectations even with more conservative reserving due to the Change disruption on claims processing. Considering those factors, management did not alter its 2024 guidance and actually pulled its outlook for 2025 on the weak final rate notice for Medicare Advantage given by the Centers for Medicare & Medicaid Services in early April. Uncertainty surrounds Humana's near-term prospects, but we still have a solid view of its long-term opportunities. This view boosts our belief that Humana shares remain attractively valued.

Price vs Fair Value

HUM is trading at a 31% discount.
Price
$325.30
Fair Value
$422.00
Uncertainty
Medium
1-Star Price
$311.94
5-Star Price
$312.20
Economic Moat
Zzpqh
Capital Allocation
Njyvvkf

Bulls Say, Bears Say

Bulls

With its prowess in Medicare Advantage plans, Humana looks likely to benefit from strong demographic trends and increasing popularity of that program in the long run.

Bears

Healthcare policy changes may remain a key threat to private insurers like Humana until affordable, universal coverage is achieved in the US.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HUM is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$316.06
Day Range
$308.54314.47
52-Week Range
$299.23540.99
Bid/Ask
$308.90 / $309.23
Market Cap
$37.23 Bil
Volume/Avg
766 / 1.7 Mil

Key Statistics

Price/Earnings (Normalized)
13.25
Price/Sales
0.36
Dividend Yield (Trailing)
1.08%
Dividend Yield (Forward)
1.08%
Total Yield
5.06%

Company Profile

Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Sector
Healthcare
Industry
Healthcare Plans
Stock Style Box
Mid Core
Total Number of Employees
67,600

Competitors

Valuation

Metric
HUM
ELV
CI
Price/Earnings (Normalized)
13.2515.5014.05
Price/Book Value
2.363.042.23
Price/Sales
0.360.730.54
Price/Cash Flow
11.3413.7112.58
Price/Earnings
HUM
ELV
CI

Financial Strength

Metric
HUM
ELV
CI
Quick Ratio
Current Ratio
Interest Coverage
7.868.494.81
Quick Ratio
No chart available

Profitability

Metric
HUM
ELV
CI
Return on Assets (Normalized)
5.46%7.36%5.00%
Return on Equity (Normalized)
17.15%20.87%16.44%
Return on Invested Capital (Normalized)
11.21%13.85%10.56%
Return on Assets
HUM
ELV
CI
See how this stock stacks up to its competitors with Morningstar Investor

Healthcare Plans Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
UNH
UnitedHealth Group IncRgwwmgcbTkftgc$448.4 Bil
ELV
Elevance Health IncVmddpzdhxRlwlgnd$124.0 Bil
CI
The Cigna GroupFqrldsmwSyqwb$100.0 Bil
CVS
CVS Health CorpKfgtqwvbcBdjlgvb$85.4 Bil
CNC
Centene CorpCycnvlvjqHyjyvl$40.8 Bil
MOH
Molina Healthcare IncTfssv$21.2 Bil
OSCR
Oscar Health Inc Class ATdbfp$4.0 Bil
ALHC
Alignment Healthcare IncFjv$978.9 Mil
CLOV
Clover Health Investments Corp Ordinary Shares - Class ALzklb$321.9 Mil

Sponsor Center